




Your IVD  
Specialists!



# ELISA for the determination of the neutralizing activity of antibodies to SARS-COV-2 variants

For Research Use




# ELISA assay for the determination of the neutralizing bioactivity of antibodies, developed upon Covid-19 or induced by vaccination, against a secondary infection (in recovered) or primary one (in vaccinated) individuals by a specific SARS-CoV-2 variant

## The assay is able to detect:

- the "WUHAN" wild strain
- the "UK" variant originally developed in United Kingdom (B.1.1.7)
- the "BR" variant established in Brazil (P.1)
- the "SA" one originated in South Africa (B.1.351)
- the "IN" recent variant spread in India (B.1.617.2)
- the the "LAMBDA" quite recent variant spread out from Peru (C.37)

## The assay is intended for testing on:

- Covid-19 recovered patients
- Vaccinated individuals



NAME	CODE	FORMAT	DESCRIPTION
ACE2-RBD Neutralization Variants	ACE2-RBDVAR.CE	16 Tests	ELISA for the determination of the neutralizing activity of antibodies to SARS-CoV-2 variants by ACE2-RBD binding inhibition

**Method:** ELISA  
**Sample:** Human plasma and sera  
**Shelf-life:** 15 months  
**Storage Temperature:** +2°...+8°C

**Performances:**  
**100% specificity**  
**100% sensitivity**

